Barterian Justin A, Rappuhn Erin, Seif Erin L, Watson Gabriel, Ham Hannah, Carlson John S
401c Erickson Hall, Michigan State University, East Lansing, MI 48824, USA.
ScientificWorldJournal. 2014 Jan 27;2014:286085. doi: 10.1155/2014/286085. eCollection 2014.
Psychotropic medications are being prescribed off-label by psychiatrists to treat preschool children diagnosed with internalizing disorders. In this review, the current state of evidence is presented for medications used to treat preschool children (ages 2-5 year olds) diagnosed with anxiety and/or depressive disorders. Eleven studies were systematically identified for this review based on a priori criteria. Overall, the available literature revealed that studies addressing the medication treatment of internalizing disorders in preschoolers are extremely limited and represent relatively weak research methodologies. Given the increasing prevalence of the use of psychotropic medications to treat preschool children and the unique challenges associated with working with this population, it is imperative that mental health practitioners are aware of the current, albeit limited, research on this practice to help make informed treatment decisions. Suggestions about how to monitor potential costs and benefits in those unique cases in which psychopharmacological treatments might be considered for young children are given. Moreover, areas of additional research for this population are discussed.
精神科医生正在超说明书使用精神药物来治疗被诊断为内化性障碍的学龄前儿童。在这篇综述中,呈现了用于治疗被诊断患有焦虑和/或抑郁障碍的学龄前儿童(2至5岁)的药物的现有证据状态。基于先验标准,系统地确定了11项研究用于本综述。总体而言,现有文献表明,针对学龄前儿童内化性障碍药物治疗的研究极其有限,且研究方法相对薄弱。鉴于使用精神药物治疗学龄前儿童的情况日益普遍,以及与该人群打交道所面临的独特挑战,心理健康从业者必须了解目前关于这种做法的研究,尽管研究有限,以便做出明智的治疗决策。文中给出了关于如何在可能考虑对幼儿进行精神药物治疗的独特案例中监测潜在成本和效益的建议。此外,还讨论了针对该人群的其他研究领域。